



IPW

AMENDMENT TRANSMITTAL LETTER (Large Entity)				Docket No. 13095A	
Applicant(s): Rober H. Harris					
Application No. 10/688,709	Filing Date 10/17/2003	Examiner David Lukton	Customer No. 23389	Group Art Unit 1653	Confirmation No. 2201
Invention: NEW USES FOR AMINO ACID ANTICONVULSANTS					
COMMISSIONER FOR PATENTS:					
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	22 -	22 =	0	x \$50.00	\$0.00
INDEP. CLAIMS	1 -	3 =	0	x \$200.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<div style="display: flex; justify-content: space-between;"><div><input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 19-1013/SSMP <div style="margin-left: 20px;"><input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.</div><input type="checkbox"/> Payment by credit card. Form PTO-2038.</div><div>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</div></div>					
<div style="text-align: center;"> _____ <i>Signature</i></div> <div>Mark J. Cohen Registration No. 32,211 Scully, Scott, Murphy & Presser 400 Garden City Plaza, Suite 300 Garden City, NY 11530 (516) 742-4343</div>			<div>Dated: March 18, 2005</div> <div style="border: 1px solid black; padding: 5px; margin-top: 10px;"><div style="text-align: center;">I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on</div><div style="text-align: center;">3/18/2005 (Date)</div><div style="text-align: center;"> _____ <i>Signature of Person Mailing Correspondence</i></div><div style="text-align: center;">Mark J. Cohen _____ <i>Typed or Printed Name of Person Mailing Correspondence</i></div></div>		
CC:					



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Robert H. Harris

Examiner: David Lukton

Serial No: 10/688,709

Art Unit: 1653

Filed: October 17, 2003

Docket: 13095A

For: NEW USES FOR AMINO ACID
ANTICONVULSANTS

Dated: March 18, 2005

Confirmation No: 2201

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE


Sirs:

In response to the Office Action dated February 18, 2005, and in accordance with the provisions of 37 C.F.R. §§1.111 and 1.143, applicant provisionally elects, with traverse, the species, (R)-N-Benzyl-2-acetamido-3-methoxypropionamide.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, P.O. Box 1450, Alexandria, VA 22313-1450 on March 18, 2005.

Dated: March 18, 2005


Mark J. Cohen